# Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

> **NCT00077311** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 160 (actual)

## Conditions studied

- Anemia
- Drug/Agent Toxicity by Tissue/Organ
- Lung Cancer
- Neutropenia

## Interventions

- **BIOLOGICAL:** darbepoetin alfa
- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** cisplatin
- **DRUG:** docetaxel
- **DRUG:** BNP7787

## Key facts

- **NCT ID:** NCT00077311
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-07
- **Final completion:** 2009-04
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2016-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00077311

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00077311, "Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00077311. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*